The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors

Mario Scartozzi, Riccardo Giampieri, Giuseppe Aprile, Donatella Iacono, Daniele Santini, Emanuela Dell'Aquila, Nicola Silvestris, Antonio Gnoni, Marta Bonotto, Marco Puzzoni, Laura Demurtas, Stefano Cascinu

Research output: Contribution to journalArticlepeer-review

Abstract

Several clinical series have demonstrated a notably low overall survival for colorectal cancer patients diagnosed with a BRAF-mutant tumor. A potentially interesting predictive role has also been suggested for BRAF-mutant colorectal cancer receiving anti-EGFR monoclonal antibodies. Although a global consensus exists in indicating BRAF as a prognostic factor with a possible predictive activity, the clinical use of BRAF mutational status in colorectal tumors is still controversial. This article reviews the current knowledge on the use and implications of BRAF mutational status in colorectal tumors, in order to define its present role in the clinical practice. Also suggested are possible treatment strategies in this prognostically challenging group of patients. Finally, a comprehensive outlook on future developments for specifically directed anti-BRAF therapy is illustrated.

Original languageEnglish
Pages (from-to)979-987
Number of pages9
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number8
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • BRAF
  • cetuximab
  • colon cancer
  • dabrafenib
  • encorafenib
  • panitumumab
  • trametinib
  • vemurafenib

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors'. Together they form a unique fingerprint.

Cite this